TRP_1170x120_3-8-19

hydrocodone

Teva gets FDA’s OK for Vantrela ER

Teva gets FDA’s OK for Vantrela ER

JERUSALEM, Israel — Teva Pharmaceutical Industries Ltd. has received Food and Drug Administration approval for Vantrela ER, an opioid pain medication with Teva’s abuse deterrence technology. Vantrela ER (hydrocodone bitartrate extended-release tablets, CII) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which other treatment options

Pernix releases Zohydro ER hydrocodone capsules with BeadTek

Pernix releases Zohydro ER hydrocodone capsules with BeadTek

MORRISTOWN, N.J. — Pernix Therapeutics Holdings Inc. has rolled out a new formulation of Zohydro Extended-Release Capsules (hydrocodone bitartrate, CII) with BeadTek technology, to U.S. pharmacies. Pernix said Monday that Zohydro ER with BeadTek is available in strengths 10 mg, 15 mg, 20 mg, 30 mg, 40 mg and 50 mg. The Food and Drug Administration (FDA) approved the updated formulation with BeadTek